Table 6.
Study | Year | Datasets | No. of Patients |
Performance | Image Modalities |
Time/ Equipment |
Category | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dice (%) | ASD (mm) | HD (mm) | Jac (%) | FPVF/FNVF (%) | MSE/RMSE (mm) | |||||||
Ji [64] | 2013 | In-house | 12 | — | — | — | MRI | 128 s/CPU | CML | |||
Wang [65] | 2015 | In-house | 30 60 |
|
|
|
— | — | — | CBCT CT |
20 min/— | CML |
Udupa [66] | 2014 | In-house | 15 | — | — | — |
/ |
— | MRI | 54 s/CPU | CML | |
Linares [19] | 2019 | In-house | 16 | — | — | — | — | CBCT | 5 min/CPU | CML | ||
Barandiaran [67] | 2009 | In-house | 12 | — | — | — | — | — | — | CT | 10 s/CPU | CML |
Orbes-Arteaga [68] | 2015 | PDDCA | 40 | — | — | — | — | — | CT | — | CML | |
Wang [69] | 2016 | PDDCA | 48 | — | — | — | — | CT | —/CPU | CML | ||
Qazi [70] | 2010 | In-house | 25 | — | — | — | — | — | CT | 3 min/CPU | CML | |
Torosdagli [71] | 2017 | PDDCA | 40 | — | <1.00 | — | — | — | CT | —/CPU | CML | |
Wu [72] | 2018 | In-house | 216 | — | — | — | — | CT | — | CML | ||
Tam [36] | 2018 | In-house | 56 | — | — | — | — | / | CT | 1 s/CPU | CML | |
Tong [73] | 2018 | In-house | 246 | — | — | — | — | — | — | CT | — | CML |
Wu [74] | 2019 | In-house | 216 | — | — | — | — | — | CT | 30 s/CPU | CML | |
Gacha [75] | 2018 | PDDCA | 30 | — | — | — | — | — | CT | — | CML | |
Spampinato [76] | 2012 | In-house | 10 | — | — | — | — | — | — | CT | — | CML |